M&A, patents & pricing, tech invasion may define Indian pharma in 2014
This article was originally published in Scrip
Brace for more action in India, with "opportunistic" mergers and acquisitions (M&A), patent and pricing related issues and a tech thrust among the key trends likely to shape the pharmaceutical sector in 2014, according some industry pundits.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.